Literature DB >> 16893988

Anti-CD25 antibody treatment of mice vaccinated and challenged with Borrelia spp. does not exacerbate arthritis but inhibits borreliacidal antibody production.

Dean T Nardelli1, Thomas F Warner, Steven M Callister, Ronald F Schell.   

Abstract

CD4(+) CD25(+) T cells are a population of regulatory T cells responsible for the modulation of the immune response in several autoimmune and infectious disease models. We previously showed that adoptive transfer of enriched CD4(+) CD25(+) T cells also plays a major role in the prevention of arthritis in Borrelia-vaccinated (Borrelia burgdorferi isolate 297) and -challenged (B. bissettii) mice. Here, we present evidence that administration of anti-CD25 antibody at the time of challenge or at later intervals fails to enhance the development of severe destructive osteoarthropathy in Borrelia-vaccinated C57BL mice. However, Borrelia-vaccinated and -challenged mice receiving anti-CD25 antibody developed decreased borreliacidal antibody titers compared to vaccinated and challenged controls. These findings suggest that additional mechanisms besides CD4(+) CD25(+) T cells are involved in the regulation of the immune response to Borrelia infection following vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893988      PMCID: PMC1539113          DOI: 10.1128/CVI.00137-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  46 in total

1.  Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance.

Authors:  Anne C Moore; Awen Gallimore; Simon J Draper; Katherine R Watkins; Sarah C Gilbert; Adrian V S Hill
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 2.  CD4+ regulatory cells as a potential immunotherapy.

Authors:  Zoltán Fehérvari; Shimon Sakaguchi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

3.  CD4(+) CD25(+) T cells prevent arthritis associated with Borrelia vaccination and infection.

Authors:  Dean T Nardelli; Joseph P Cloute; K H Kevin Luk; Jose Torrealba; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

4.  Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells.

Authors:  Aurélie Trenado; Muriel Sudres; Qizhi Tang; Sébastien Maury; Frédéric Charlotte; Sylvie Grégoire; Mark Bonyhadi; David Klatzmann; Benoît L Salomon; José L Cohen
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

5.  Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors.

Authors:  Xinquan Wang; Mathias Rickert; K Christopher Garcia
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

Review 6.  Factors that regulate naturally occurring T regulatory cell-mediated suppression.

Authors:  Elena Goleva; Ivan D Cardona; Liang-Shiou Ou; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2005-11       Impact factor: 10.793

7.  Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion.

Authors:  Santiago Zelenay; Thiago Lopes-Carvalho; Iris Caramalho; Maria Francisca Moraes-Fontes; Manuel Rebelo; Jocelyne Demengeot
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 8.  Tolerance, not immunity, crucially depends on IL-2.

Authors:  Thomas R Malek; Allison L Bayer
Journal:  Nat Rev Immunol       Date:  2004-09       Impact factor: 53.106

9.  Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi.

Authors:  Matthew A Burchill; Dean T Nardelli; Douglas M England; David J DeCoster; John A Christopherson; Steven M Callister; Ronald F Schell
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice.

Authors:  Corey A Amlong; Dean T Nardelli; Sara Heil Peterson; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-02
View more
  7 in total

Review 1.  Lyme arthritis: current concepts and a change in paradigm.

Authors:  Dean T Nardelli; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

2.  Interleukin-10 (IL-10) inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis.

Authors:  Emily S Hansen; Velinka Medić; Joseph Kuo; Thomas F Warner; Ronald F Schell; Dean T Nardelli
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

3.  Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection.

Authors:  Kevin N Couper; Paula A Lanthier; Georgia Perona-Wright; Lawrence W Kummer; Wangxue Chen; Stephen T Smiley; Markus Mohrs; Lawrence L Johnson
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

4.  Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species.

Authors:  Nicholas J Kotloski; Dean T Nardelli; Sara Heil Peterson; Jose R Torrealba; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

5.  Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity.

Authors:  Sara Heil Peterson; Dean T Nardelli; Thomas F Warner; Steven M Callister; Jose R Torrealba; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-03-14

6.  Regulatory T Cells Contribute to Resistance against Lyme Arthritis.

Authors:  Emily M Siebers; Elizabeth S Liedhegner; Michael W Lawlor; Ronald F Schell; Dean T Nardelli
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

Review 7.  Hamster and murine models of severe destructive Lyme arthritis.

Authors:  Erik Munson; Dean T Nardelli; Brian K Du Chateau; Steven M Callister; Ronald F Schell
Journal:  Clin Dev Immunol       Date:  2012-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.